Although there is no cure for Psoriasis, research is going on into many psoriasis treatments that will help manage the symtpoms. Johnson & Johnson's subsidiary Centocor Inc. said Monday the Food and Drug Administration will review its application for experimental drug CNTO 1275 for the treatment of psoriasis, a skin disease.

Centocor is seeking approval for the late-stage drug, also known as ustekinumab, to treat adults with chronic moderate-to-severe plaque psoriasis, which results from the overproduction of skin cells and causes red, scaly plaques that itch.

Psoriasis affects about 3% of the global population. It can start at any age but usually between the age of 11 and 45 and most often at puberty.

The main symptom is grey or silvery flaky patches on the skin which are red and inflamed underneath. The areas of the body that are most commonly affected are the scalp, elbows, knees, navel, palms, ears and groin.

The cause of Psoriasis is not that well understood but it is beleived to be immune system related.